stockrowHaleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
Follow HLN
Alert me
Haleon PLC Sponsored ADR (HLN) Return on assets
Haleon PLC Sponsored ADR's return on assets over the twelve months to 30 June 2026 was 0.00%, down 5.1 percentage points from fiscal 2025 (5.06%). Over the past ten years it has ranged from 0.00% (fiscal 2019) to 8.04% (fiscal 2021); the current reading is higher than 86% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −1.67% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 5.06% | 0.79 |
| FY2024 | 4.27% | 1.21 |
| FY2023 | 3.06% | 0.14 |
| FY2022 | 2.92% | (5.12) |
| FY2021 | 8.04% | 4.69 |
| FY2020 | 3.35% | 3.35 |
| FY2019 | 0.00% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ZTS Zoetis Inc. compare | 17.8% |
| UTHR United Therapeutics Corporation compare | 17.1% |
| NBIX Neurocrine Biosciences, Inc. compare | 14.2% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.44% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 1.27% |
| TAK Takeda Pharmaceutical Co. compare | 0.00% |
| HLN Haleon PLC Sponsored ADR | 0.00% |
| ELAN Elanco Animal Health Incorporated compare | −1.46% |
| VTRS Viatris Inc. compare | −1.67% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on HLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement